• Can Direct-acting Antivirals Treatment of HCV Reactivate Herpesvirus Infection?

Can Direct-acting Antivirals Treatment of HCV Reactivate Herpesvirus Infection?

Researchers report reactivation of herpesvirus in 10 patients with hepatitis C virus (HCV) infection treated with direct-acting antiviral (DAA) agents in the November issue of Clincial Gastroenterology and Hepatology. Christie Perelló et al performed a case series analysis of reactivation of herpesvirus in patients with HCV infection treated with DAA

Read more
  • Gilead Sells Sofosbuvir to Egypt for About $10 per Pill

Gilead Sells Sofosbuvir to Egypt for About $10 per Pill

In Egypt, pharmaceutical companies are testing a complicated deal to sell hepatitis C drugs at a fraction of their usual cost while imposing tight restrictions intended to protect lucrative markets in the West. According to the New York Times, Gilead Sciences Inc. is selling its sofosbuvir to the Egyptian government

Read more
  • Medicaid Denies Almost 50% of Prescriptions for Hepatitis C Drugs in 4 States

Medicaid Denies Almost 50% of Prescriptions for Hepatitis C Drugs in 4 States

Medicaid programs in Delaware, Maryland, New Jersey, and Pennsylvania denied nearly half of all claims in the past year for direct-acting antiviral (DAA) hepatitis C drugs, according to an analysis of pharmacy data presented at the American Association for the Study of Liver Diseases 2015 Liver Meeting. The finding confirms

Read more
  • Bradycardia After Sofosbuvir and Daclatasvir in 2 Patients Receiving Amiodarone

Bradycardia After Sofosbuvir and Daclatasvir in 2 Patients Receiving Amiodarone

Two patients receiving treatment with amiodarone developed bradycardia within 2 hours after taking sofosbuvir and daclatasvir  for hepatitis C, researchers report in the November issue of Gastroenterology. Patients treated with amiodarone should be continuously monitored within the first 48 hours after receiving these hepatitis C drugs, say the authors of the Brief Report. Sofosbuvir and

Read more
  • Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Sofosbuvir-based regimens, with or without daclatasvir, greatly improve the clinical status of patients who develop fibrosing cholestatis hepatitis (FCH) after liver transplantation for hepatitis C virus (HCV) infection, and most of the patients achieve a sustained virologic response (SVR), researchers report in the November issue of Clinical Gastroenterology and Hepatology. These results

Read more
  • Public Health Officials Call for Wider Access to HCV Drugs

Public Health Officials Call for Wider Access to HCV Drugs

Experts from the Public Health Service and President Obama’s Advisory Council on HIV/AIDS are calling on federal and state Medicaid officials to widen access to prescription drugs that could cure tens of thousands of people with hepatitis C virus (HCV) infection. They say restrictions on the drugs imposed by many

Read more
  • Hepatitis C Drugs Might be Cost Effective but Demand Could Bust the Healthcare Bank

Hepatitis C Drugs Might be Cost Effective but Demand Could Bust the Healthcare Bank

Treating patients with hepatitis C virus (HCV) infection using recently approved direct-acting agents can be cost effective, but will also have substantial effects on healthcare costs, researchers show. Recently approved drugs cure more than 90% of patients with hepatitis C and could make the liver disease rare in the United

Read more

New Ways to Treat HCV Infection After Liver Transplant

New direct-acting agents against hepatitis C virus (HCV) can cure the infection when it recurs in patients with liver transplants. Researchers reported findings from 3 separate studies at the 65th Annual Meeting of the American Association for the Study of Liver Diseases last week in Boston. HCV is the leading

Read more